Compare
GT Biopharma, Inc. vs Lite Strategy, Inc. vs Unicycive Therapeutics, Inc. vs Lifevantage Corp
| Latest fiscal year | GT Biopharma, Inc. GTBP | Lite Strategy, Inc. LITS | Unicycive Therapeutics, Inc. UNCY | Lifevantage Corp LFVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | $0 | n/a | $182.59M |
| Revenue growth (YoY) | n/a | -100.0% | n/a | -20.1% |
| Gross margin | n/a | n/a | n/a | 77.6% |
| Operating margin | n/a | n/a | n/a | 3.3% |
| Net margin | n/a | n/a | n/a | 2.8% |
| Net income | -$28.35M | -$15.95M | -$26.55M | $5.07M |
| EPS (Diluted) | -$6.68 | -$2.39 | -$1.67 | $0.40 |
| Operating cash flow | -$12.91M | -$20.84M | -$31.32M | $10.24M |
| Free cash flow | n/a | -$20.84M | -$31.34M | $6.67M |
| Cash & equivalents | $6.81M | $18.01M | $29.20M | n/a |
| Total assets | $8.11M | $18.29M | $49.13M | $62.11M |
| Total liabilities | n/a | $1.35M | $18.94M | $28.52M |
| Shareholders' equity | $5.79M | $16.93M | $30.20M | $33.59M |
| Return on year-end equity | -490.0% | -94.2% | -87.9% | 15.1% |
| Shares outstanding | 25.53M | 6.66M | 22.11M | 12.52M |
Revenue, most recent five fiscal years
| Fiscal year | GT Biopharma, Inc. | Lite Strategy, Inc. | Unicycive Therapeutics, Inc. | Lifevantage Corp |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $0 Ended 2025-06-30 | $675.0K Ended 2023-12-31 | $182.59M Ended 2026-06-30 |
| 1 year earlier | $0 Ended 2019-12-31 | $65.30M Ended 2024-06-30 | $951.0K Ended 2022-12-31 | $228.53M Ended 2025-06-30 |
| 2 years earlier | n/a | $48.82M Ended 2023-06-30 | n/a | $200.16M Ended 2024-06-30 |
| 3 years earlier | n/a | $40.70M Ended 2022-06-30 | n/a | $213.40M Ended 2023-06-30 |
| 4 years earlier | n/a | $34.80M Ended 2021-06-30 | n/a | $206.36M Ended 2022-06-30 |